January 27, 2020

CMIC Co., Ltd.
SUSMED Co., Ltd.


Tokyo- January 27, 2020 -CMIC Co., Ltd. (henceforth “CMIC”) and SUSMED Co., Ltd. (henceforth “SUSMED”), which conducts research and development for digital therapies, will begin offering simplified big data analysis solutions using AI that will allow researchers to gain rapid and valuable insights into big data, including real-world data (RWD). This service will start today, January 27, 2020. These simplified analysis solutions consist of a service where CMIC performs data cleansing* on pharmaceutical companies’ RWD and other big data in order to enable simplified analysis, after which SUSMED’s automated AI analysis systems are used on the data, allowing for a simplified analysis that is faster compared to existing processes. These solutions will enable efficient pre-analysis and are expected to contribute to shortening the time needed to set up clinical trials and perform analysis for academic publications.

* A process where repetitions, mistakes, and inconsistent notation are identified within a database, after which they are deleted, revised, or normalized, improving the quality of data and making it suitable for analysis.

Expectations have been increasing within the medical field in recent years regarding the use of day-to-day RWD collected from individual patients in medical settings. The environment surrounding RWD in Japan is heading for a big turning point in expanding its use, and in April 2019 the Clinical Evaluation Expert Committee of the Japan Pharmaceutical Manufacturers Association’s Drug Evaluation Committee conducted discussions regarding the extent to which existing domestic RWD could be used in drug development. However, unlike that of clinical trial data collected using established, reliable methods, the analysis of RWD, which often includes missing or biased data, has not been fully developed due to the costs that accompany the massive time and effort needed for data cleansing and analysis.

By combining CMIC’s total operation services and SUSMED’s unique medical technologies, we will significantly shorten the time needed to plan analysis and to create and run analysis programs, and we will contribute to the realization of speedy and efficient clinical trials.

■About CMIC Group

CMIC Group started business in 1992 as the first CRO in Japan, and the company today provides comprehensive support services for the development, manufacturing, sales, and marketing of pharmaceutical products. Also, the company operates to respond to diversifying needs by managing the Healthcare Business sector and developing and selling diagnostic pharmaceuticals and orphan drugs. CMIC Group has developed a unique business model called Pharmaceutical Value Creator (PVC) based on its abundant accumulated experience and knowledge as a CRO pioneer. CMIC utilizes the PVC to create new value in the healthcare field.

For more information, visit CMIC Groupʼs website: https://en.cmicgroup.com/

■ About SUSMED Co., Ltd.

SUSMED Co., Ltd., is a research and development firm that is advancing digital therapies. In addition to developing an app for treating insomnia, SUSMED provides a universal platform for developing medical apps, along with clinical trial support systems and automated AI analysis systems. SUSMED is advancing digital therapy grounded in technology, with patents in medical apps and blockchain applications in medical treatment. https://www.susmed.co.jp/

【Contact Information】
CMIC HOLDINGS Co., Ltd. PR group
TEL: 03-6779-8200 E-mail: pr@cmic.co.jp

SUSMED Co., Ltd.
E-mail: support@susmed.co.jp